Broader community enrollment improves external validity by capturing patients with comorbidities and real-world treatment patterns, while familiarizing clinicians with toxicity management before ...

Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus ...

In an interview with Targeted OncologyTM, Daniel Heng, MD, of the University of Calgary, discusses the recent FDA approval of belzutifan (Welireg) plus lenvatinib (Lenvima) for patients with advanced ...

Rusfertide was approved by the FDA 1 for adults with polycythemia who require phlebotomy, based on results from the phase 3 ...

Those questions point to research that is still needed, Nieva says. This includes the role of deintensifying imaging and ...

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus ...

Nieva also discussed the ROS1 fusion partner subgroup. Whether the partner was CD74 or another gene, the overall response ...

Andrew Kuykendall, MD, discusses where rusfertide (Mimrylo) may fit within the treatment paradigm for polycythemia vera and ...

Giada Bianchi, MD, discusses tailoring therapy in myeloma, addressing ultra-high-risk disease, and amyloidosis becoming a ...

In this segment, Dr. Luciano Costa provides practical considerations for managing patients with newly diagnosed multiple ...

The FDA has approved the kinase inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally ...

In this segment, Dr. Peter Voorhees and Dr. Doris Hansen discuss the safety profile and post-treatment management of CAR ...